Historical Valuation
Supernus Pharmaceuticals Inc (SUPN) is now in the Fair zone, suggesting that its current forward PE ratio of 19.24 is considered Fairly compared with the five-year average of 21.51. The fair price of Supernus Pharmaceuticals Inc (SUPN) is between 43.57 to 68.49 according to relative valuation methord.
Relative Value
Fair Zone
43.57-68.49
Current Price：51.11
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Supernus Pharmaceuticals Inc (SUPN) has a current Price-to-Book (P/B) ratio of 2.69. Compared to its 3-year average P/B ratio of 1.96 , the current P/B ratio is approximately 37.34% higher. Relative to its 5-year average P/B ratio of 1.98, the current P/B ratio is about 35.85% higher. Supernus Pharmaceuticals Inc (SUPN) has a Forward Free Cash Flow (FCF) yield of approximately 2.49%. Compared to its 3-year average FCF yield of 6.99%, the current FCF yield is approximately -64.34% lower. Relative to its 5-year average FCF yield of 7.30% , the current FCF yield is about -65.82% lower.
P/B
Median3y
1.96
Median5y
1.98
FCF Yield
Median3y
6.99
Median5y
7.30
Competitors Valuation Multiple
AI Analysis for SUPN
The average P/S ratio for SUPN competitors is 34.09, providing a benchmark for relative valuation. Supernus Pharmaceuticals Inc Corp (SUPN.O) exhibits a P/S ratio of 3.46, which is -89.86% above the industry average. Given its robust revenue growth of 9.34%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SUPN
1Y
3Y
5Y
Market capitalization of SUPN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SUPN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SUPN currently overvalued or undervalued?
Supernus Pharmaceuticals Inc (SUPN) is now in the Fair zone, suggesting that its current forward PE ratio of 19.24 is considered Fairly compared with the five-year average of 21.51. The fair price of Supernus Pharmaceuticals Inc (SUPN) is between 43.57 to 68.49 according to relative valuation methord.
What is Supernus Pharmaceuticals Inc (SUPN) fair value?
SUPN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Supernus Pharmaceuticals Inc (SUPN) is between 43.57 to 68.49 according to relative valuation methord.
How does SUPN's valuation metrics compare to the industry average?
The average P/S ratio for SUPN's competitors is 34.09, providing a benchmark for relative valuation. Supernus Pharmaceuticals Inc Corp (SUPN) exhibits a P/S ratio of 3.46, which is -89.86% above the industry average. Given its robust revenue growth of 9.34%, this premium appears unsustainable.
What is the current P/B ratio for Supernus Pharmaceuticals Inc (SUPN) as of Jan 11 2026?
As of Jan 11 2026, Supernus Pharmaceuticals Inc (SUPN) has a P/B ratio of 2.69. This indicates that the market values SUPN at 2.69 times its book value.
What is the current FCF Yield for Supernus Pharmaceuticals Inc (SUPN) as of Jan 11 2026?
As of Jan 11 2026, Supernus Pharmaceuticals Inc (SUPN) has a FCF Yield of 2.49%. This means that for every dollar of Supernus Pharmaceuticals Inc’s market capitalization, the company generates 2.49 cents in free cash flow.
What is the current Forward P/E ratio for Supernus Pharmaceuticals Inc (SUPN) as of Jan 11 2026?
As of Jan 11 2026, Supernus Pharmaceuticals Inc (SUPN) has a Forward P/E ratio of 19.24. This means the market is willing to pay $19.24 for every dollar of Supernus Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Supernus Pharmaceuticals Inc (SUPN) as of Jan 11 2026?
As of Jan 11 2026, Supernus Pharmaceuticals Inc (SUPN) has a Forward P/S ratio of 3.46. This means the market is valuing SUPN at $3.46 for every dollar of expected revenue over the next 12 months.